about
5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: synthesis, stability and reductive activationSuccessful Baylis-Hillman reaction of acrylamide with aromatic aldehydes.Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterizationAn essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugsOptimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.Probing the active site of alpha-class rat liver glutathione S-transferases using affinity labeling by monobromobimane.Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor.Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signalingDesign of anticancer prodrugs for reductive activation.Targeted prodrug approaches for hormone refractory prostate cancer.A novel high-yield synthesis of aminoacyl p-nitroanilines and aminoacyl 7-amino-4-methylcoumarins: Important synthons for the synthesis of chromogenic/fluorogenic protease substrates.Insects: an underrepresented resource for the discovery of biologically active natural productsDesign and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.Design and synthesis of novel iminothiazinylbutadienols and divinylpyrimidinethiones as ARE inducers.In vitro and in vivo anti-inflammatory effects of a novel 4,6-bis ((E)-4-hydroxy-3-methoxystyryl)-1-phenethylpyrimidine-2(1H)-thione.5'-(2-Nitrophenylalkanoyl)-2'-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation.Neuropeptide Y acylation chemistry in aqueous solution: significance to synthesis of a peptide-based photoaffinity label.The contribution of helical potential to the in vitro receptor binding activity of a neuropeptide Y N-terminal deletion fragment.In honor of Professor Lester A. Mitscher on the occasion of his 80(th) birthday.Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).Unravelling the role of SNM1 in the DNA repair system of Trypanosoma brucei.Improving the Specificity of the Prostate-Specific Antigen Substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a Promoiety.Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage.A convenient biphasic process for the monosilylation of symmetrical 1,n-primary diolsMonobromobimane as an affinity label of the xenobiotic binding site of rat glutathione S-transferase 3-3Resonance energy transfer between sites in rat liver glutathione S-transferase, 1-1, selectively modified at cysteine-17 and cysteine-111A Simple One-Pot Procedure for the Direct Conversion of Alcohols to Azides via Phosphate ActivationN-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustardPeptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA)Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activationDesign, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuriaImmunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small moleculesDesign, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein InteractionNrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction
P50
Q28377710-BC482AE2-4FC3-4FF8-9278-6F769A83ED7EQ33424628-2605EE8E-D1AE-4512-B3DD-A83373686A0AQ34413813-D8A73AD5-F4B1-4683-8B6F-CD794646440EQ34942136-716E5BC3-06E4-43D2-90BA-06363A8D98A2Q35842879-01DFF56F-61EC-426E-9357-B46ADF73F1FAQ36280075-8ECFF6C1-3678-40C5-B300-0CCD31599EC7Q36463474-70E38D86-12BD-4D61-9B32-1AAF832BCBA2Q37184089-25695DDB-F1C9-4549-9CA9-B9B0EC5F37BBQ37238437-E3D330CA-BE9E-4691-899D-F0DEA7981A20Q38295983-4280AA7B-E084-40A9-9F6D-7BE508E4584FQ38322083-A8682278-DA2D-45CB-A6BE-057B3BA088D9Q38656223-C6EC77B7-E131-457B-9CFC-C3E240C17760Q38772480-C72CE2BB-95B4-4089-B360-D017654B8FECQ40258806-6D2CC866-BAE9-49A8-BB06-7611D66AB514Q41981782-67E166E4-C394-457A-BCDF-5AC063EB1DC9Q42708079-36511144-77DF-431B-B117-697C45E47276Q44555580-F3311375-FBB7-40E4-AAC9-13BA2EA99155Q48216661-5EAF4D60-749C-40C2-A7A8-8F1A98574479Q48237904-B9EDB7D6-2A2D-4FD9-A321-22EE90B57F83Q48417240-88D42C8A-F47D-4F92-9490-8D6C2573B733Q51736112-23A8B155-4A48-40C8-85FE-6DB394BC031FQ52657468-90E5FEB3-D7F4-4E4D-9777-F4846092660EQ52958555-925D72C7-CB51-467F-8C33-23DEDB71E8A1Q53591532-B089085E-9960-4541-B43E-92B4E8C2988BQ56587691-81DD6E43-A2E7-47FD-B849-AEFD3EF0C23EQ72036844-D39A67D8-65BF-4B10-AE37-61E269ECA909Q73106766-45FC7B21-7DC2-4024-A881-7C2DE2D924DBQ73983401-8AAA5C4A-04BA-4264-9C85-BCC4FACE9BA3Q81460997-347E8EEC-AEDD-4524-B883-D6F9AF75BB61Q86554678-C3A28605-9285-472F-9C3A-86207E0B821EQ87405032-46406A36-3DAC-4388-928B-1F60746D0E32Q88150174-85E40482-B114-4AE5-AA0E-965E071EA740Q91446261-F8EE4673-7627-4787-BBC5-657202B7988CQ91822958-09A8A519-F685-4BEC-9565-717D0249CABBQ94543918-CE21CF5E-5A9F-4FB5-B556-95611D9A05BC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Longqin Hu
@ast
Longqin Hu
@en
Longqin Hu
@es
Longqin Hu
@nl
Longqin Hu
@sl
type
label
Longqin Hu
@ast
Longqin Hu
@en
Longqin Hu
@es
Longqin Hu
@nl
Longqin Hu
@sl
prefLabel
Longqin Hu
@ast
Longqin Hu
@en
Longqin Hu
@es
Longqin Hu
@nl
Longqin Hu
@sl
P106
P31
P496
0000-0002-1799-5652